Back to the Top
Dear All,
Does anyone have experience in doing a BE/bioavailability assessment for a conversion of vials to PFS formats for monoclonals? Is it required by the regulatory agency?
What factors need to be considered when converting from vials to PFS?
Thanks
Zeepal
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "PFS vs. Vial BE" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)